North America Colorectal Cancer Screening Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 7.15 Billion |
| Market Size (2029) | USD 9.89 Billion |
| CAGR (2024 - 2029) | 6.70 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
North America Colorectal Cancer Screening Market Analysis
The North America Colorectal Cancer Screening Market size is estimated at USD 7.15 billion in 2024, and is expected to reach USD 9.89 billion by 2029, growing at a CAGR of 6.70% during the forecast period (2024-2029).
- The North American colorectal cancer screening market is experiencing growth due to several factors, such as the increasing prevalence of colorectal cancer, technological advancements, and cancer prevention initiatives. The high prevalence of colorectal cancers in the region is one of the major factors driving the market growth, as it is expected to increase the usage of colorectal cancer screening tests.
- For instance, according to data published by the Canadian Cancer Society in May 2024, colorectal cancer is expected to be the fourth most commonly diagnosed cancer in Canada in 2024. In addition, according to the same source, 25,200 new colorectal cancer cases are estimated to be diagnosed in Canada in 2024. Similarly, according to the data published by the International Agency for Research on Cancer in February 2024, the number of new colorectum cancer cases was reported to be 16.1 thousand cases in 2022 and is estimated to reach 17.5 thousand cases in Mexico by 2025. Thus, the increasing prevalence of colorectal cancer is driving the need for screening, which is expected to contribute to market growth during the forecast period significantly. Moreover, colorectal cancer prevention initiatives are expected to boost the market growth. For instance, according to the data updated by Ohio State University in 2023, the Ohio Colorectal Cancer Prevention Initiative (OCCPI) is a statewide initiative in Ohio, United States, to screen newly diagnosed colorectal cancer (CRC) patients and their biological relatives for Lynch syndrome. This cancer-causing condition occurs when a person inherits a mutation in one of four genes. These initiatives increase the awareness of colorectal cancer screening, thereby boosting the demand, and are expected to drive market growth during the forecast period.
- Thus, the above factors, such as the rising prevalence of colorectal cancer and cancer prevention initiatives, are expected to boost the market growth. However, high screening test costs are expected to impede market growth during the forecast period.
North America Colorectal Cancer Screening Market Trends
Guaiac Fecal Occult Blood Test (gFOBT) is Expected to be Hold a Significant Share in the Market During the Forecast Period
- The guaiac fecal occult blood test (gFOBT) is one of the tests used to detect colorectal cancer (CRC). It involves detecting hidden blood in the feces and identifying cancer cells or tumors in the colon or rectum. The guaiac fecal occult blood test is often preferred over other screening tests due to its high efficacy in detecting colorectal cancer. Thus, it is expected to hold a significant market share. Other factors, such as the rising prevalence of colorectal cancer and the increasing usage of guaiac fecal occult blood tests (gFOBT), are expected to boost segment growth.
- For example, in April 2022, an article published by the Multidisciplinary Digital Publishing Institute (MDPI) stated that CRC was considered one of the most common cancers in Canada, with around 24,800 cases projected to be diagnosed in 2021. Although the incidence of CRC among adults under the age of 50 represents approximately 8% of CRC cases in Canada, recent studies have shown that the incidence of colorectal cancer in younger people is rising rapidly in Canada. Thus, the rising prevalence of colorectal cancer is expected to boost the usage of guaiac fecal occult blood tests (gFOBT).
- Also, advancements made by market players are driving increased utilization of the products within this segment. For example, in June 2022, W.H.P.M. Inc. obtained 510(k) marketing approval from the United States FDA for Hemosure Accu-Reader A100, a guaiac-based fecal occult blood test (gFOBT). Thus, the approval of the new products will increase the availability of these gFOBT tests, thereby boosting market growth in the coming years.
The United States is Expected to be Hold a Significant Market Share During the Forecast Period
- The United States is expected to hold a significant share of the colorectal cancer screening market in North America due to the robust healthcare infrastructure for cancer screening and the rising burden of colorectal cancer. Also, awareness programs and the launch of new products are expected to augment the market's growth in the United States during the forecast period.
- For instance, according to the data published by the American Cancer Society in 2024, 106,590 new cases of colon cancer and 46,220 cases of rectal cancer are estimated to be in the United States by the end of 2024. Moreover, according to the same source, around 106,970 cases were estimated to have colon cancers, and 46,050 cases were estimated to have rectum cancer in 2023. Thus, the country's high incidence of colon and rectum cancers is expected to boost market growth.
- Also, according to the same source, it has been observed that screening can help prevent colorectal cancers by detecting and removing precancers in the colon, rectum, and uterine cervix, and screening can also reduce mortality for these cancers. Thus, the rising importance of colorectal cancer screening is also expected to boost market growth.
- Moreover, major market players' rising product approvals, recommendations, and launches are expected to boost market growth, increasing access to technologically advanced products. For instance, in March 2024, Guardant Health Inc. stated that the US FDA Medical Devices Advisory Committee, reviewing the Molecular and Clinical Genetics Panel, strongly recommended the FDA approval of Guardant Health's Shield blood test. This test is designed for colorectal cancer (CRC) screening in adults aged 45 and above. Thus, the factors above, such as the rising prevalence of colorectal cancer and the new product recommendations, are expected to boost the market growth in the region during the forecast period.
North America Colorectal Cancer Screening Industry Overview
The North American colorectal cancer screening market is fragmented due to the presence of many small and large market players. These market players are involved in various strategic activities such as agreements, partnerships, and developments to increase the product portfolio of the companies in the region. Some key North American colorectal cancer screening market players are Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Novigenix SA, Siemens Healthineers, and Sysmex Corporation.
North America Colorectal Cancer Screening Market Leaders
-
Abbott Laboratories
-
Epigenomics Inc.
-
Exact Sciences Corporation
-
Clinical Genomics Technologies Pty Ltd.
-
Hemosure Inc.
*Disclaimer: Major Players sorted in no particular order
North America Colorectal Cancer Screening Market News
- May 2024: Geneoscopy Inc. received approval from the US FDA for its non-invasive colorectal cancer screening test, ColoSense. It is indicated as a screening test for adults 45 years of age or older who are at typical average risk for developing colorectal cancer.
- May 2024: Exact Sciences Corp. presented its strategies and advancements for improving colorectal cancer screening rates and outcomes in Washington, DC. The data include Cologuard, a non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus.
North America Colorectal Cancer Screening Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Colorectal Cancer
- 4.2.2 Technological advancements and Increasing Cancer Prevention Initiatives
-
4.3 Market Restraints
- 4.3.1 High Screening Tests Costs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Screening Tests
- 5.1.1 Stool-based Tests
- 5.1.1.1 Fecal Immunochemical Test (FIT)
- 5.1.1.2 Guaiac-based Fecal Occult Blood Test (gFOBT)
- 5.1.1.3 Stool DNA Test
- 5.1.2 Colonoscopy
- 5.1.3 CT Colonography (Virtual Colonoscopy)
- 5.1.4 Flexible Sigmoidoscopy
- 5.1.5 Other Screening Tests
-
5.2 By End User
- 5.2.1 Hospitals
- 5.2.2 Diagnostic Centers/Laboratories
- 5.2.3 Other End Users
-
5.3 Geography
- 5.3.1 United States
- 5.3.2 Canada
- 5.3.3 Mexico
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Clinical Genomics Technologies Pty Ltd
- 6.1.3 Epigenomics Inc.
- 6.1.4 Exact Sciences Corporation
- 6.1.5 F. Hoffmann-La Roche AG
- 6.1.6 Hemosure Inc.
- 6.1.7 Novigenix SA
- 6.1.8 Quidel Corporation
- 6.1.9 Siemens Healthineers AG
- 6.1.10 Sysmex Corporation
- 6.1.11 EKF Diagnostics
- 6.1.12 MAINZ BIOMED N.V.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNorth America Colorectal Cancer Screening Industry Segmentation
As per the report's scope, colorectal cancer (CRC) is also known as bowel cancer and colon cancer. It is a cancer of the colon or rectum, usually located at the digestive tract's lower end. Colorectal cancer screening tests use kits and various medical devices to diagnose cancer. The North American colorectal cancer screening market is segmented by screening tests, end users, and geography. The market is segmented by screening tests into stool-based tests, colonoscopy, CT colonography, flexible sigmoidoscopy, and other screening tests. The other screening tests include liquid biopsy, double-contrast barium enema (DCBE), and other tests. By end users, the market is segmented into hospitals, diagnostic centers/laboratories, and other end users. The other end users include gastrointestinal clinics and specialty care centers. The market is segmented by geography into the United States, Canada, and Mexico. The report offers the value (in USD) for the above segments.
| By Screening Tests | Stool-based Tests | Fecal Immunochemical Test (FIT) |
| Guaiac-based Fecal Occult Blood Test (gFOBT) | ||
| Stool DNA Test | ||
| By Screening Tests | Colonoscopy | |
| CT Colonography (Virtual Colonoscopy) | ||
| Flexible Sigmoidoscopy | ||
| Other Screening Tests | ||
| By End User | Hospitals | |
| Diagnostic Centers/Laboratories | ||
| Other End Users | ||
| Geography | United States | |
| Canada | ||
| Mexico |
North America Colorectal Cancer Screening Market Research FAQs
How big is the North America Colorectal Cancer Screening Market?
The North America Colorectal Cancer Screening Market size is expected to reach USD 7.15 billion in 2024 and grow at a CAGR of 6.70% to reach USD 9.89 billion by 2029.
What is the current North America Colorectal Cancer Screening Market size?
In 2024, the North America Colorectal Cancer Screening Market size is expected to reach USD 7.15 billion.
Who are the key players in North America Colorectal Cancer Screening Market?
Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, Clinical Genomics Technologies Pty Ltd. and Hemosure Inc. are the major companies operating in the North America Colorectal Cancer Screening Market.
What years does this North America Colorectal Cancer Screening Market cover, and what was the market size in 2023?
In 2023, the North America Colorectal Cancer Screening Market size was estimated at USD 6.67 billion. The report covers the North America Colorectal Cancer Screening Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Colorectal Cancer Screening Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Colorectal Cancer Screening Industry Report
Statistics for the 2024 North America Colorectal Cancer Screening market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. North America Colorectal Cancer Screening analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
